Stephanie Lake1, Thomas Kerr2, Rielle Capler3, Jeannie Shoveller1, Julio Montaner2, M-J Milloy4. 1. British Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, 608-1081 Burrard Street, Vancouver, BC V6Z 1Y6, Canada; School of Population and Public Health, University of British Columbia, 2206 East Mall, Vancouver, BC V6T 1Z3, Canada. 2. British Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, 608-1081 Burrard Street, Vancouver, BC V6Z 1Y6, Canada; Department of Medicine, University of British Columbia, St. Paul's Hospital, 608-1081 Burrard Street, Vancouver, BC V6Z 1Y6, Canada. 3. Interdisciplinary Studies Graduate Program, University of British Columbia, 270-2357 Main Mall, Vancouver, BC V6T 1Z4, Canada. 4. British Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, 608-1081 Burrard Street, Vancouver, BC V6Z 1Y6, Canada; Department of Medicine, University of British Columbia, St. Paul's Hospital, 608-1081 Burrard Street, Vancouver, BC V6Z 1Y6, Canada. Electronic address: uhri-mjsm@cfenet.ubc.ca.
Abstract
BACKGROUND: Reforms to the legal status of medical and non-medical cannabis are underway in many jurisdictions, including Canada, as are renewed efforts to scale-up HIV treatment-as-prevention (TasP) initiatives. It has been suggested that high-intensity cannabis use may be associated with sub-optimal HIV treatment outcomes. Thus, using data from a setting with a community-wide treatment-as-prevention (TasP) initiative coinciding with increasing access to medical cannabis, we sought to investigate the possible impact of high-intensity cannabis use on HIV clinical outcomes. METHODS: Data was derived from the ACCESS study, a prospective cohort of HIV-positive people who use illicit drugs (PWUD) in Vancouver, Canada. Cohort data was confidentially linked to comprehensive clinical profiles, including records of all antiretroviral therapy (ART) dispensations and longitudinal plasma HIV-1 RNA viral load (VL) monitoring. We used generalized estimating equations (GEEs) to estimate the longitudinal bivariable and multivariable relationships between at least daily cannabis use and two key clinical outcomes: overall engagement in ART care, and achieving a non-detectable VL among ART-exposed participants. RESULTS: Between December 2005 and June 2015, 874 HIV-positive PWUD (304 [35%] non-male) were included in this study. In total, 788 (90%) were engaged in HIV care at least once over the study period, of whom 670 (85%) achieved non-detectable VL at least once. In multivariable analyses, ≥ daily cannabis use did not predict lower odds of ART care (Adjusted Odds Ratio [AOR]: 1.02, 95% confidence interval [CI]: 0.77-1.36) or VL non-detectability among ART-exposed (AOR: 0.96, 95% CI: 0.75-1.21). Upon testing for potential interactions, ≥ daily cannabis use was found to be negatively associated with ART engagement during periods of binge alcohol use (p<0.05). CONCLUSION: With the exception of frequent cannabis use during periods of binge alcohol use, our results showed no statistically significant impact of daily cannabis use on the likelihood of ART care or VL non-detectability among ART-exposed HIV-positive PWUD. These findings are reassuring in light of the impending legalization of cannabis in Canada and ongoing efforts to expand TasP initiatives.
BACKGROUND: Reforms to the legal status of medical and non-medical cannabis are underway in many jurisdictions, including Canada, as are renewed efforts to scale-up HIV treatment-as-prevention (TasP) initiatives. It has been suggested that high-intensity cannabis use may be associated with sub-optimal HIV treatment outcomes. Thus, using data from a setting with a community-wide treatment-as-prevention (TasP) initiative coinciding with increasing access to medical cannabis, we sought to investigate the possible impact of high-intensity cannabis use on HIV clinical outcomes. METHODS: Data was derived from the ACCESS study, a prospective cohort of HIV-positivepeople who use illicit drugs (PWUD) in Vancouver, Canada. Cohort data was confidentially linked to comprehensive clinical profiles, including records of all antiretroviral therapy (ART) dispensations and longitudinal plasma HIV-1 RNA viral load (VL) monitoring. We used generalized estimating equations (GEEs) to estimate the longitudinal bivariable and multivariable relationships between at least daily cannabis use and two key clinical outcomes: overall engagement in ART care, and achieving a non-detectable VL among ART-exposed participants. RESULTS: Between December 2005 and June 2015, 874 HIV-positive PWUD (304 [35%] non-male) were included in this study. In total, 788 (90%) were engaged in HIV care at least once over the study period, of whom 670 (85%) achieved non-detectable VL at least once. In multivariable analyses, ≥ daily cannabis use did not predict lower odds of ART care (Adjusted Odds Ratio [AOR]: 1.02, 95% confidence interval [CI]: 0.77-1.36) or VL non-detectability among ART-exposed (AOR: 0.96, 95% CI: 0.75-1.21). Upon testing for potential interactions, ≥ daily cannabis use was found to be negatively associated with ART engagement during periods of binge alcohol use (p<0.05). CONCLUSION: With the exception of frequent cannabis use during periods of binge alcohol use, our results showed no statistically significant impact of daily cannabis use on the likelihood of ART care or VL non-detectability among ART-exposed HIV-positive PWUD. These findings are reassuring in light of the impending legalization of cannabis in Canada and ongoing efforts to expand TasP initiatives.
Authors: Patricia E Molina; Peter Winsauer; Ping Zhang; Edith Walker; Leslie Birke; Angela Amedee; Curtis Vande Stouwe; Dana Troxclair; Robin McGoey; Kurt Varner; Lauri Byerley; Lynn LaMotte Journal: AIDS Res Hum Retroviruses Date: 2010-11-23 Impact factor: 2.205
Authors: Julio S G Montaner; Viviane D Lima; Rolando Barrios; Benita Yip; Evan Wood; Thomas Kerr; Kate Shannon; P Richard Harrigan; Robert S Hogg; Patricia Daly; Perry Kendall Journal: Lancet Date: 2010-07-16 Impact factor: 79.321
Authors: Donald I Abrams; Joan F Hilton; Roslyn J Leiser; Starley B Shade; Tarek A Elbeik; Francesca T Aweeka; Neal L Benowitz; Barry M Bredt; Bradley Kosel; Judith A Aberg; Steven G Deeks; Thomas F Mitchell; Kathleen Mulligan; Peter Bacchetti; Joseph M McCune; Morris Schambelan Journal: Ann Intern Med Date: 2003-08-19 Impact factor: 25.391
Authors: Fabienne Marcellin; Caroline Lions; Eric Rosenthal; Perrine Roux; Philippe Sogni; Linda Wittkop; Camelia Protopopescu; Bruno Spire; Dominique Salmon-Ceron; François Dabis; Maria Patrizia Carrieri Journal: Drug Alcohol Rev Date: 2016-04-13
Authors: Evan Wood; Thomas Kerr; Brandon D L Marshall; Kathy Li; Ruth Zhang; Robert S Hogg; P Richard Harrigan; Julio S G Montaner Journal: BMJ Date: 2009-04-30
Authors: Hudson Reddon; Kora DeBeck; M Eugenia Socias; Stephanie Lake; Huiru Dong; Mohammad Karamouzian; Kanna Hayashi; Thomas Kerr; M-J Milloy Journal: Am J Public Health Date: 2020-08-20 Impact factor: 9.308
Authors: Allison R Webel; Carolyn Smith; Joseph Perazzo; J Craig Phillips; Hamed Al Battashi; Carol Dawson-Rose Journal: West J Nurs Res Date: 2019-04-21 Impact factor: 1.967
Authors: Kiyomi Tsuyuki; Steven J Shoptaw; Yusuf Ransome; Gordon Chau; Carlos E Rodriguez-Diaz; Ruth K Friedman; Kriengkrai Srithanaviboonchai; Sue Li; Matthew J Mimiaga; Kenneth H Mayer; Steven A Safren Journal: AIDS Behav Date: 2019-03
Authors: Douglas Bruce; Alida M Bouris; Shannon Bowers; Olivia Blocker; Soo Young Lee; Mary F Glidden; John A Schneider; Daniel H Reirden Journal: Addict Res Theory Date: 2019-06-26
Authors: Risha Irvin; Geetanjali Chander; Oluwaseun Falade-Nwulia; Jacquie Astemborski; Laura Starbird; Gregory D Kirk; Mark S Sulkowski; David L Thomas; Shruti H Mehta Journal: Addict Behav Date: 2019-04-23 Impact factor: 4.591